San Jose, Costa Rica, January 19th, 2026 — SteinCares announced today that Moody’s Investors Service has assigned the company an AA credit rating with Stable outlook, highlighting its solid financial position, resilient business model, and disciplined operational execution across Latin America’s pharmaceutical sector.
The rating recognizes SteinCares’ robust cash flow generation, prudent capital structure, and proven ability to scale its business through an integrated “one-stop-shop” platform that connects global pharmaceutical innovation with local healthcare needs.
SteinCares’ strong corporate governance— supported by a diverse and experienced Board of Directors and a minority equity investment from the International Finance Corporation (IFC)—reinforces the company’s long-term strategy and sustainable growth trajectory across the region.
“This rating validates the strength and stability of our business model and reinforces confidence in SteinCares’ strategy for Latin America,” said Mitchell Waserstein, CEO of SteinCares. “It underscores our ongoing commitment to operational excellence, financial discipline, and expanding patient access to innovative treatments.”
According to Moody’s, the rating is supported by SteinCares’ diversified business model across innovative medicines, biosimilars, and complex generics; strong cash flow generation and conservative financial profile characterized by low leverage and solid liquidity; robust governance structure strengthened by IFC’s minority equity investment; and disciplined approach to regional expansion. These factors position SteinCares among Latin America’s leading specialty pharmaceutical companies with a proven track record of sustainable growth.
Investor Outlook
The AA rating underscores SteinCares’ position as a trusted partner for global licensors and investors seeking long-term, sustainable growth opportunities in Latin America’s healthcare sector. It reflects not only the company’s financial strength but also its operational resilience, sound governance, and proven ability to scale innovative healthcare solutions across diverse markets. Notably, SteinCares’ credit rating stands above the sovereign ratings of most countries where it operates, reinforcing its financial stability and role as a reliable partner in emerging markets.
About SteinCares
SteinCares is a leading specialty pharmaceutical company dedicated to expanding patient access to innovative and cost-effective treatments across Latin America. With more than 45 years of experience and an integrated “one-stop-shop” platform across 30 countries of Latin America and the Caribbean, SteinCares combines deep local expertise, regulatory agility, and end-to-end operational capabilities — from licensing and commercialization to market access and patient support.
For more information, visit www.steincares.com and follow SteinCares on LinkedIn
